Wall Street Zen Downgrades Aclaris Therapeutics to "Sell"

Biotech firm's stock rating cut from "hold" to "sell" by research firm

Published on Mar. 7, 2026

Got story updates? Submit your updates here. ›

Wall Street Zen, a financial research firm, has downgraded the stock of Aclaris Therapeutics (NASDAQ:ACRS) from a "hold" rating to a "sell" rating in a new report. Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for dermatological conditions.

Why it matters

The downgrade from Wall Street Zen could put pressure on Aclaris Therapeutics' stock price and raise concerns among investors about the company's future prospects. As a clinical-stage biotech firm, Aclaris Therapeutics' performance is closely watched by the investment community.

The details

In its report, Wall Street Zen cited concerns about Aclaris Therapeutics' financial performance and the progress of its drug development pipeline. The firm noted that the company has struggled to meet analyst expectations for revenue and earnings, and that some of its key drug candidates have faced delays or setbacks in clinical trials.

  • Wall Street Zen issued its downgrade report on Saturday, March 7, 2026.

The players

Aclaris Therapeutics

A clinical-stage biopharmaceutical company focused on developing novel therapies for dermatological conditions.

Wall Street Zen

A financial research firm that provides investment analysis and ratings on publicly traded companies.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

The downgrade of Aclaris Therapeutics by Wall Street Zen highlights the challenges facing clinical-stage biotech companies as they work to develop and commercialize new drugs. Investors will be closely watching the company's future performance and pipeline progress in the coming months.